Search - tctmd.com

Displaying 21 - 40 of 254

Sort: Relevancy | Date

News Daily News

Majority of US Adults Have High Long-term Risk of CVD: NHANES

Michael O'Riordan

June 13, 2025

News Daily News

PREVENT Risk Calculator Works Well in Patients With High and Low Lp(a)

Michael O'Riordan

June 10, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Opinion CV Team Dispatch

May 2025 Dispatch for the CV Team

L.A. McKeown

May 20, 2025

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

Lp(a) Genetics Differ Between Populations but Have Similar Clinical Impact

Yael L. Maxwell

May 05, 2025

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

L.A. McKeown

April 10, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Daily News

Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE

Yael L. Maxwell

February 14, 2025

News Daily News

Higher Lp(a) Indicates Greater Chance of Stenosis on CCTA in Patients With Chest Pain

Yael L. Maxwell

January 13, 2025

News Daily News

Top General Cardiology and Prevention News of 2024

Caitlin E. Cox

December 30, 2024

News Daily News

Lp(a) Can Vary Over Time in ASCVD Patients With High Baseline Levels: OCEAN(a)-DOSE

Yael L. Maxwell

December 13, 2024

News Conference News AHA 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Caitlin E. Cox

November 21, 2024

Presentation AHA 2024

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Presenter: Steven E. Nissen

November 18, 2024

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

News Daily News

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

Michael O'Riordan

November 13, 2024

Presentation TCT 2024

TCT 260: Lipoprotein (a) and Endoluminal Disease Phenotype

Presenter: TsungYing Tsai

October 30, 2024

Presentation TCT 2024

TCT 1019: Coronary Plaque Characteristics Assessed by Optical Coherence Tomography and Plasma Lipoprotein (a) Levels in Patients With Acute Coronary Syndrome

Presenter: Francesca Maria Di Muro

October 29, 2024

Presentation TCT 2024

I Measured Lipoprotein (a): What was I Thinking, and Now What Do I Do?

Presenter: Dipti Itchhaporia

October 29, 2024

Advertisement

Majority of US Adults Have High Long-term Risk of CVD: NHANES

PREVENT Risk Calculator Works Well in Patients With High and Low Lp(a)

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

May 2025 Dispatch for the CV Team

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Lp(a) Genetics Differ Between Populations but Have Similar Clinical Impact

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

What’s Going to Be Hot at ACC 2025?

Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE

Higher Lp(a) Indicates Greater Chance of Stenosis on CCTA in Patients With Chest Pain

Top General Cardiology and Prevention News of 2024

Lp(a) Can Vary Over Time in ASCVD Patients With High Baseline Levels: OCEAN(a)-DOSE

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

TCT 260: Lipoprotein (a) and Endoluminal Disease Phenotype

TCT 1019: Coronary Plaque Characteristics Assessed by Optical Coherence Tomography and Plasma Lipoprotein (a) Levels in Patients With Acute Coronary Syndrome

I Measured Lipoprotein (a): What was I Thinking, and Now What Do I Do?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content